Drugs and Devices

FDA approval for "biogeneric" drugs

Richard Morrison — Fri, 3 Oct 2008 14:16:58 -0700

Cholesterol Drug Scare Shenanigans

Steven J. Milloy — Thu, 4 Sep 2008 13:00:17 -0700

Why is the editor of the New England Journal of Medicine encouraging a cancer scare over the cholesterol-lowering drug Vytorin? Is he overcompensating for past bad behavior?

Public Funding for Stem Cell Research: Boon or Boondoggle?

Christine Hall — Thu, 4 Sep 2008 10:51:00 -0700

Debates over the ethics of research using human embryonic stem cells continue long after the Bush Administration’s ban on federal tax-funding for such research. But, a new report from the Competitive Enterprise Institute calls into question whether, ethics aside, stem cell research is even a sensible expenditure of taxpayer dollars.

Sick Patients Need Cutting-Edge Drugs

Gregory Conko — Sat, 23 Aug 2008 00:00:00 -0700

The story of Anna Tomalis trying to recieve a compassionate usage exemption from the FDA to treat her cancer.

Generic Pharmaceutical Association Annual Policy Conference 2008

Ryan Lynch — Fri, 22 Aug 2008 15:02:32 -0700

Reform Needed at the Food and Drug Administration

Richard Morrison — Thu, 14 Aug 2008 13:05:53 -0700

FDA's Bad Medicine

Gregory Conko — Wed, 13 Aug 2008 00:00:00 -0700

How the dispersed knowledge problem affects drug safety analysis and how markets and technology will help patients

Drugs and Devices FAQ

Ryan Lynch — Mon, 21 Jul 2008 00:00:00 -0700

"Politics of Pain" Campaign to Defend Patients' Rights

Richard Morrison — Fri, 16 May 2008 04:46:39 -0700

CEI fighting for millions of Americans who live in pain because their doctors are afraid of being harassed or arrested by the DEA.

Are Imports the Solution to High Drug Prices?

Richard Morrison — Fri, 25 Apr 2008 14:34:35 -0700

With the high cost of pharmaceutical drugs playing a central role in the national debate over health care, many policymakers have endorsed the idea of buying U.S.-made drugs from other countries, where prices controls make them far cheaper. Competitive Enterprise Institute Senior Fellow Gregory Conko, however, explains why such a policy of drug “reimportation” would ultimately slow innovation and mean fewer life-saving drugs in the new study Drug Reimportation’s Dangerous Allure: A Misguided Const-Control Measure Guaranteed to Harm Patient Care.